Skip to content

Study · Animal study (in vivo) · mouse · 2010

9 results

Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.

Muzumdar RH, Huffman DM, Calvert JW, Jha S, Weinberg Y, Cui L, Nemkal A, Atzmon G, Klein L, Gundewar S, Ji SY, Lavu M, Predmore BL, Lefer DJ

Arteriosclerosis, thrombosis, and vascular biology22 Jul 2010Cited by 142 (Europe PMC)

PMID20651283 (opens in a new tab)PMCIDPMC2941397 (opens in a new tab)DOI10.1161/atvbaha.110.205997 (opens in a new tab)PepBankPUB-20651283
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with myocardial ischemia and reperfusion, HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at 2 mg/kg.

    In plain wordsIn mice, the humanin analog HNG shrank heart damage after blocked blood flow, most at 2 mg/kg.

    Peptide
    Humanin
    Outcome
    DecreaseInfarct size relative to area-at-risk
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    2 mg/kg (maximal reduction) · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    HNG reduced infarct size relative to the area-at-risk in a dose-dependent fashion, with a maximal reduction at the dose of 2 mg/kg.
    2 context sentences
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with myocardial ischemia and reperfusion, HNG therapy enhanced left ventricular ejection fraction.

    In plain wordsIn mice, the humanin analog HNG improved the heart's pumping fraction after blocked blood flow.

    Peptide
    Humanin
    Outcome
    IncreaseLeft ventricular ejection fraction
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    HNG therapy enhanced left ventricular ejection fraction
    3 context sentences
    Summary · context
    Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770).
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with myocardial ischemia and reperfusion, HNG therapy preserved postischemic left ventricular end-diastolic and end-systolic dimensions.

    In plain wordsIn mice, the humanin analog HNG kept the heart chamber sizes closer to normal after blocked blood flow.

    Peptide
    Humanin
    Outcome
    Direction not reportedPostischemic left ventricular dimensions
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    preserved postischemic left ventricular dimensions (end-diastolic and end-systolic), resulting in improved cardiac function.
    3 context sentences
    Summary · context
    Left ventricular function was evaluated at 1 week after ischemia using high-resolution, 2D echocardiography (VisualSonics Vevo 770).
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with myocardial ischemia and reperfusion, HNG treatment significantly increased phosphorylation of AMPK in the heart.

    In plain wordsIn mice, the humanin analog HNG raised AMPK activation in the heart after blocked blood flow.

    Peptide
    Humanin
    Outcome
    IncreaseAMPK phosphorylation in the heart
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion.
    3 context sentences
    Summary · context
    Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion.
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with myocardial ischemia and reperfusion, HNG treatment significantly increased phosphorylation of endothelial nitric oxide synthase in the heart.

    In plain wordsIn mice, the humanin analog HNG raised eNOS activation in the heart after blocked blood flow.

    Peptide
    Humanin
    Outcome
    IncreaseEndothelial nitric oxide synthase phosphorylation in the heart
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion.
    3 context sentences
    Summary · context
    Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion.
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with myocardial ischemia and reperfusion, HNG treatment attenuated Bcl-2-associated X protein levels.

    In plain wordsIn mice, the humanin analog HNG lowered a cell-death protein (Bax) in the heart after blocked blood flow.

    Peptide
    Humanin
    Outcome
    DecreaseBax level after ischemia and reperfusion
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion.
    3 context sentences
    Summary · context
    Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion.
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with myocardial ischemia and reperfusion, HNG treatment attenuated B-cell lymphoma-2 levels.

    In plain wordsIn mice, the humanin analog HNG lowered Bcl-2 levels in the heart after blocked blood flow.

    Peptide
    Humanin
    Outcome
    DecreaseBcl-2 level after ischemia and reperfusion
    Study

    mousen: not reported in source

    Left coronary artery occlusion 45 min then reperfusion
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with HNG significantly increased phosphorylation of AMPK and phosphorylation of endothelial nitric oxide synthase in the heart and attenuated Bcl-2-associated X protein and B-cell lymphoma-2 levels following myocardial ischemia and reperfusion.
    3 context sentences
    Summary · context
    Myocardial cell signaling pathways and apoptotic markers were assessed at various time points (0 to 24 hours) following reperfusion.
    Summary · context
    Male C57BL6/J mice (8 to 10 week old) were subjected to 45 minutes of left coronary artery occlusion followed by a 24-hour reperfusion.
    Summary · context
    HNG or vehicle was administered IP 1 hour prior or at the time of reperfusion.
  8. 08LabIn vitro (cells)Efficacy outcome

    In cardiomyocytes exposed to daunorubicin in vitro, HNG improved cell survival.

    In plain wordsIn cells, the humanin analog HNG helped heart muscle cells survive a toxic drug.

    Peptide
    Humanin
    Outcome
    IncreaseCardiomyocyte survival
    Study

    n: not reported in source

    Cardiomyocytes exposed to daunorubicin
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro.
    1 context sentence
    Summary · context
    Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro.
  9. 09LabIn vitro (cells)Efficacy outcome

    In cardiomyocytes exposed to daunorubicin in vitro, HNG decreased apoptosis.

    In plain wordsIn cells, the humanin analog HNG reduced cell death in heart muscle cells exposed to a toxic drug.

    Peptide
    Humanin
    Outcome
    DecreaseCardiomyocyte apoptosis
    Study

    n: not reported in source

    Cardiomyocytes exposed to daunorubicin
    Outcome group
    Myocardial injury · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HNG improved cardiomyocyte survival and decreased apoptosis in response to daunorubicin in vitro.
    1 context sentence
    Summary · context
    Cardiomyocyte survival and apoptosis in response to HNG were assessed in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.